Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Olivotto I, et al. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Lancet. 2020. PMID: 32871100 Clinical Trial.
Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week.
Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, Elliott PM, Hagege A, Kuusisto J, Linhart A, Nordbeck P, Olivotto I, Pietilä-Effati P, Namdar M. Pieroni M, et al. J Am Coll Cardiol. 2021 Feb 23;77(7):922-936. doi: 10.1016/j.jacc.2020.12.024. J Am Coll Cardiol. 2021. PMID: 33602475 Free article. Review.
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry.
Lopes LR, Losi MA, Sheikh N, Laroche C, Charron P, Gimeno J, Kaski JP, Maggioni AP, Tavazzi L, Arbustini E, Brito D, Celutkiene J, Hagege A, Linhart A, Mogensen J, Garcia-Pinilla JM, Ripoll-Vera T, Seggewiss H, Villacorta E, Caforio A, Elliott PM; Cardiomyopathy Registry Investigators Group. Lopes LR, et al. Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13;9(1):42-53. doi: 10.1093/ehjqcco/qcac006. Eur Heart J Qual Care Clin Outcomes. 2022. PMID: 35138368 Free PMC article.
New trends in treatment of hypertrophic cardiomyopathy.
Hagège AA, Desnos M. Hagège AA, et al. Arch Cardiovasc Dis. 2009 May;102(5):441-7. doi: 10.1016/j.acvd.2009.03.008. Epub 2009 May 12. Arch Cardiovasc Dis. 2009. PMID: 19520330 Free article. Review.
Management and outcomes of hypertrophic cardiomyopathy in young adults.
Baron É, Karam N, Donal E, Puscas T, Mirabel M, Bacher A, Wahbi K, Mazzella JM, Jeunemaitre X, Reant P, Hagège A; REMY, GEREMY working groups of the French Society of Cardiology. Baron É, et al. Arch Cardiovasc Dis. 2021 Jun-Jul;114(6-7):465-473. doi: 10.1016/j.acvd.2020.12.006. Epub 2021 Mar 17. Arch Cardiovasc Dis. 2021. PMID: 33744178 Free article.
Prognostic value of the 12-lead surface electrocardiogram in sarcomeric hypertrophic cardiomyopathy: data from the REMY French register.
Ledieu N, Larnier L, Auffret V, Marie C, Fargeau D, Donal E, Mirabel M, Jeunemaitre X, Puscas T, Marijon E, Reynaud A, Ritter P, Lafitte S, Mabo P, Réant P, Daubert C, Hagège AA; REMY Working Group of the French Society of Cardiology. Ledieu N, et al. Among authors: hagege aa. Europace. 2020 Jan 1;22(1):139-148. doi: 10.1093/europace/euz272. Europace. 2020. PMID: 31603495
165 results